<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>IMGN on FinanClub</title>
    <link>https://finan.club/tags/imgn/</link>
    <description>Recent content in IMGN on FinanClub</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Sun, 06 Aug 2023 12:16:34 +0000</lastBuildDate><atom:link href="https://finan.club/tags/imgn/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>1116 IMGN</title>
      <link>https://finan.club/us/imgn/</link>
      <pubDate>Sun, 06 Aug 2023 12:16:34 +0000</pubDate>
      
      <guid>https://finan.club/us/imgn/</guid>
      <description>score:1116
Chances: ImmunoGen&amp;rsquo;s Q2 earnings show an encouraging adoption of the sole-marketed drug Elahere. ImmunoGen delivered better-than-expected earnings and revenue surprises for the quarter ended June 2023. The company announced a multi-target license and option agreement to develop next-generation antibody-drug conjugates. ImmunoGen made it to the Zacks Rank #1 (Strong Buy) momentum stocks list.</description>
    </item>
    
  </channel>
</rss>
